详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Analysis of the Curative Effect of Neoadjuvant Therapy on Pancreatic Cancer

93| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China [2]Department of Public Health, Chengdu Medical College, Chengdu, China [3]Department of Anesthesiology, Gulinxian People’s Hospital of Sichuan Province, Luzhou, China [4]Department of Digestive Surgery, School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong [5]Department of Orthopedics, Shanghai Institute of Traumatology and Orthopaedics, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China [6]Department of Art, Art College, Southwest Minzu University, Chengdu, China [7]Department of Neuroscience, Beijing Institute of Basic Medical Sciences, Beijing, China

出处：

DOI：

ISSN：

关键词： pancreatic cancer neoadjuvant chemotherapy neoadjuvant chemo-radiotherapy treatment neoadjuvant therapy

摘要：

The prevalence of pancreatic cancer is sharply increasing recently, which significantly increases the economic burden of the population. At present, the primary treatment of resectable pancreatic cancer is surgical resection, followed by chemotherapy with or without radiation. However, the recurrence rates remain high even after R0 resection. This treatment strategy does not distinguish undetected metastatic disease, and it is prone to postoperative complications. Neoadjuvant therapies, including neoadjuvant chemotherapy and radiotherapy, is being increasingly utilized in borderline resectable as well as resectable pancreatic cancer. This review summarized and discussed clinical trials of neoadjuvant therapy for pancreatic cancer, comparing resection rates, outcome measures, and adverse reactions between neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 3 区医学

小类 | 3 区肿瘤学

最新[2023]版：

大类 | 3 区医学

小类 | 3 区肿瘤学

JCR分区：

出版当年[2021]版：

Q2 ONCOLOGY

最新[2023]版：

Q2 ONCOLOGY

影响因子： 3.5 最新[2023版] 4 最新五年平均 5.738 出版当年[2021版] 6.122 出版当年五年平均 6.244 出版前一年[2020版] 4.7 出版后一年[2022版]

第一作者：

第一作者机构： [1]Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Optimal preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma [2]Neoadjuvant and Adjuvant Therapy for Non-Small Cell Lung Cancer [3]Tislelizumab plus chemotherapy sequential neochemoradiotherapy therapy as total neoadjuvant therapy in locally advanced esophageal squamous cell carcinoma (ETNT) [4]Tislelizumab Plus Chemotherapy Sequential Neoadjuvant Therapy for Non-cCR Patients After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ETNT): An Exploratory Study [5]A Phase Ib Trial of Neoadjuvant Low-Dose Radiation Therapy, Chemotherapy, and Durvalumab for Potentially Resectable Stage III NSCLC [6]Phase Ib Trial of Neoadjuvant Low Dose Radiotherapy, Chemotherapy, and Durvalumab for Potentially Resectable Stage III NSCLC [7]Induction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery for patients with locally advanced rectal cancer: a systematic review and meta-analysis. [8]Early Results of the Survival Results and Possible Prognostic Factors for Locally Advanced Nasopharyngeal Carcinoma Patients Treated With Neoadjuvant Chemotherapy Followed With Concurrent Chemoradiation Therapy [9]Neoadjuvant low-dose radiotherapy plus durvalumab and chemotherapy for potentially resectable stage III NSCLC: A phase Ib dose-escalation study [10]Neoadjuvant therapy with immunoagent (nivolumab) or placebo plus chemotherapy followed by surgery and adjuvant treatment in subjects with resectable esophageal squamous cell carcinoma: study protocol of a randomized, multicenter, double blind, phase II trial (NATION-2203 trial)